Improving the clinical trial landscape for Parkinson syndromes in Germany
Year: 2026
Type: article
Abstract: Germany has a longstanding tradition of excellence in neuroscience and Parkinson’s research, supported by outstanding academic institutions, specialized clinical centers, and a strong scientific community. Building on this strong foundation, the country now has the opportunity to transform its clinical research landscape into a more integrated ecosystem for Parkinson syndromes. Despite major advances in molecular understanding, biomarker development, and therapeutic innovation, important structural, regulatory, financial, and organizational barriers continue to limit the full translational potential of German Parkinson research. Participants in an expert workshop identified identify recurring challenges, including fragmented trial infrastructures, slow and bureaucratic regulatory procedures, insufficient funding for investigator-initiated clinical research, limited integration of patient organizations, and suboptimal patient recruitment pathways. This workshop-derived perspective outlines a strategic framework to elevate Germany from a country with excellent individual centers to a globally competitive and integrated hub for innovative Parkinson clinical research. Key recommendations include transforming the German Parkinson Study Group into a nationally coordinated, service-oriented trial network; establishing centralized digital and regulatory infrastructures; diversifying public and philanthropic funding; implementing platform and observational trial structures; strengthening incentives for participating centers; and enhancing patient engagement through national registries, decentralized trial approaches, real-world data based evidence surveillance, and systematic integration of patient organizations. The authors argue that Germany must move beyond isolated university-based structures toward a nationally coordinated and highly efficient research ecosystem capable of rapidly delivering disease-modifying and precision medicine trials. Such a transformation could strengthen Germany’s international position in neurodegenerative disease research and accelerate therapeutic innovation for patients with Parkinson syndromes.
Source: Journal of Neural Transmission
Authors: Günter Höglinger, Karla Eggert, Joseph Classen, Thilo van Eimeren, Matthias Höllerhage, Wolfgang H. Jost, Jan Kassubek, Jochen Klucken, Thomas Koeglsperger, Rejko Krüger, Thomas Müller, Monika Pötter-Nerger, Peter Riederer, Alexander Storch, Jürgen Winkler, Ullrich Wüllner, Christoph Schindler, Paul Lingor, The German Parkinson’s Experts Meeting Group
Institutions: German Center for Neurodegenerative Diseases, LMU Klinikum, Munich Cluster for Systems Neurology, Ludwig-Maximilians-Universität München, Universitätsklinikum Gießen und Marburg, University Hospital Leipzig, University Hospital Cologne, Medizinische Hochschule Hannover, Saarland University, University Hospital Ulm, Centre Hospitalier de Luxembourg, University of Luxembourg, Luxembourg Centre for Systems Biomedicine, Luxembourg Institute of Health, St. Joseph-Krankenhaus, Universität Hamburg, University Medical Center Hamburg-Eppendorf, University of Würzburg, University of Rostock, Universitätsklinikum Erlangen, University Hospital Bonn, Technical University of Munich
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,690
OpenAlex ID: W7223465751